Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/26/2025

Treatment for Cerebral Venous Sinus Thrombosis (CVST)

Initial Management

  • The American College of Chest Physicians recommends immediate anticoagulation with either intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) as the first-line treatment for CVST, even in patients with hemorrhagic lesions 1, 2
  • Anticoagulation should be started immediately after diagnosis confirmation, regardless of the presence of intracranial hemorrhage that occurred as a consequence of CVST 3, 2
  • Either intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin can be used as initial treatment, with a strength of evidence based on guidelines from the American College of Chest Physicians 4, 2
  • Parenteral anticoagulation therapy should be continued until the patient has stabilized clinically, as recommended by the American College of Chest Physicians 4
  • All patients should be admitted to a stroke unit for close monitoring and specialized care, according to the American Heart Association/American Stroke Association 2

Evidence Supporting Anticoagulation

  • Anticoagulation prevents thrombus propagation, increases recanalization chances, and reduces mortality and severe disability, with a moderate strength of evidence based on a meta-analysis of two randomized trials 3
  • A small prospective cohort study of 30 children with CVST reported 3 deaths among 8 untreated children compared with no deaths among 22 treated children, providing low-quality evidence for the effectiveness of anticoagulation 5
  • Anticoagulation is associated with an absolute reduction in risk of death or dependency of 13%, based on a meta-analysis of two randomized trials with a moderate strength of evidence 4

Special Considerations

  • Dexamethasone may be considered in specific scenarios with significant white matter edema causing mass effect and neurological deterioration (4-8 mg/day oral or IV), with a low strength of evidence based on expert opinion 3
  • Dexamethasone should not be used routinely in all CVST cases, particularly in asymptomatic patients without significant mass effect, according to the American Academy of Neurology 3

Transition to Oral Anticoagulation

  • After clinical stabilization, patients should be switched from parenteral anticoagulation to oral anticoagulants, as recommended by the American College of Chest Physicians with a high strength of evidence 4, 2
  • Duration of anticoagulation depends on underlying etiology, with a moderate strength of evidence based on guidelines from the American College of Chest Physicians 4, 2

Management of Complications

  • Control of seizures with appropriate anticonvulsants is recommended, with a high strength of evidence based on guidelines from the American Academy of Neurology 5
  • Management of elevated intracranial pressure is crucial, with a moderate strength of evidence based on expert opinion 5

Follow-up Recommendations

  • Neurological and ophthalmological follow-up is recommended, especially during the first year, due to risk of visual loss from increased intracranial pressure, with a moderate strength of evidence based on guidelines from the American Heart Association/American Stroke Association 5
  • Investigate underlying prothrombotic conditions, as this affects treatment duration, with a high strength of evidence based on guidelines from the American College of Chest Physicians 2
  • Monitor for cognitive and neurological sequelae that may require rehabilitation and longer-term therapy, with a moderate strength of evidence based on expert opinion 5

Cautions and Pitfalls

  • Discontinue oral contraceptives in affected patients, as they may increase risk of recurrent CVST, with a moderate strength of evidence based on guidelines from the American College of Obstetricians and Gynecologists 5

Anticoagulation Management in Cerebral Venous Sinus Thrombosis with Intracranial Hemorrhage

Pathophysiology of Hemorrhage without Anticoagulation

Clinical Evidence of Hemorrhage Prior to Treatment

Impact of Anticoagulation on Outcomes

Practical Guidance on Anticoagulation in the Presence of Hemorrhage